


Summary of Extramural Support

Funding for the 2010-2011 academic year includes \$12,305,820 and \$4,330,016 in awards administered through the Office of Sponsored Programs and the South Alabama Medical Science Foundation, respectively.

Extramural Funds Totals for Last 5 Years

2007	20,222,905
2008	20,818,609
2009	20,047,172
2010	44,124,327*
2011	16,635,836



*Includes 14.5 million dollar facilities improvement grant from NIH

**EXTRAMURAL FUNDING
(OCTOBER 1, 2010 – SEPTEMBER 30, 2011)**

BIOCHEMISTRY & MOLECULAR BIOLOGY

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Donna Cioffi	NIH 5 R00 HL089361-04	Inactivation of Endothelial I _{src} Through Calcium-Phosphate Complexation	\$248,999.00
William Gerthoffer & Rahke Gupte	NIH 5 R01 HL077726-07	Small Heat Shock Proteins in Smooth Muscle Plasticity	\$334,125.00
William Gerthoffer	NIH 5 R21 HL097220-02	Molecular Determinants of Smooth Muscle Phenotype in Pulmonary Hypertension	\$185,625.00
Sachin Gupte	NIH 5 R01 HL085352-05	Regulation of Vascular Smooth Muscle Calcium by NADPH Redox	\$367,500.00
Sachin Gupte	NIH/University of Maryland 120014	Cardiac Energy Metabolism in Heart Failure (Subcontract)	\$20,353.00
Richard Honkanen	NIH 1 R01 HL110937-01	Methods to Enable Cholesterol Catabolism in Human Monocyte Derived Macrophages	\$359,126.00
Petra Rocic & Rebecca Hutchinson	AHA 11PRE 7690011	Regulation of Coronary Collateral Growth by microRNA in the Metabolic Syndrome	\$22,180.00
Petra Rocic & William Gerthoffer	NIH 5 R01 HL093052-04	Regulation of Coronary Collateral Growth in the Metabolic Syndrome	\$362,552.00

BIOCHEMISTRY & MOLECULAR BIOLOGY (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Petra Rocic & Tracy Dodd	NIH 5 R01 HL093052-04S1	Regulation of Coronary Collateral by microRNA in the Metabolic Syndrome (Supplement)	\$42,833.00
		Total	\$1,943,293.00

BIOMEDICAL LIBRARY

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Judith Burnham	NIH/University of Maryland SE 0001597	Exhibit at the Alabama Chapter, American Physical Therapy Association	\$2,000.00
Justin Robertson	NIH/University of Maryland 110186	Alabama Health Infonet for Public Libraries	\$1,966.00
Beverly Rossini	NIH/University of Maryland 110240	Medical Association State of Alabama Exhibit Award Through the National Network of Libraries of Medicine SEA	\$1,707.00
Beverly Rossini & Jie Li	NIH/University of Maryland 110255	Alabama Pharmacy Association Annual Meeting Exhibit Grant Through the National Network of Libraries of Medicine SEA	\$2,000.00
		Total	\$7,673.00

CELL BIOLOGY & NEUROSCIENCE

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Mikhail Alexeyev	NIH 5R01 RR031286-02	Mouse Models for Mitochondrial Disorders Caused by mtDNA Mutations	\$358,888.00
Valentina Grishko	Fidia Farmaceutici, S.p.A.	Effect of Hymovis/HYADD4-G on Viability and Function of Human OA Chondrocytes	\$40,000.00
Wensheng Lin	NNMS TA 3026-A-1-03	The Role of the PERK-eIF2alpha Pathway in MS/EAE	\$137,500.00
Wensheng Lin	NIH 1R01 NS073132-01A1	The Effects of the Unfolded Protein Response on Medulloblastoma	\$324,844.00
Sarah Sayner	AHA 11GRNT7430039	Bicarbonate Stimulated Soluble Adenylyl Cyclase Regulates Pulmonary Endothelial Barrier	\$82,500.00
Glenn Wilson	NIH 5 R01 ES003456-25 Revised	Environmental Beta Cell Toxins - Mechanisms of Action	\$305,613.00
		Total	\$1,209,345.00

CENTER FOR STRATEGIC HEALTH INNOVATIONS

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Dan Roach	NCHI 90R C0055-01-SUPP	The Alabama Regional Extension Center	\$620,806.00

CENTER FOR STRATEGIC HEALTH INNOVATIONS (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Carl Taylor	HHSOC/ADPH C10114295 (CEP-15-QW2-12)	Health Care Facility Planning Assistance Pilot Project 2012	\$64,459.00
Carl Taylor	HHSOS/ADPH C10114296 (CEP-16-QW-12)	Regional Response Planning 2012	\$60,614.00
Carl Taylor	HHSOS/ADPH C10114294 (CEP-14-QW2-12)	Advance Regional Response Training Center - Roadshow ARRTC 2012	\$257,391.00
Carl Taylor	HHSOS/ADPH C10114298 (CEP-3-QW2-12)	Alabama Incident Management System - AIMS 2012	\$154,902.00
Carl Taylor	HHSOS/ADPH C10114292 (CEP-13-QW2-12)	Advanced Regional Response Training Center – Basic ARRTC 2012	\$497,877.00
Carl Taylor	HHSOS/ADPH C10114297 (CEP-12-QW-1-12)	Advanced Regional Response Training Center – Advanced ARRTC 2012	\$138,024.00
		Total	\$1,794,073.00

EMERGENCY MEDICINE

Principal Investigator	Agency	Project Title	Fiscal Year Funding
W. Scott McNair	Boehringer Ingelheim	A Randomized, Double-Blind, Double Dummy, Active Controlled, Parallel Group, Forced Titration Study to Compare the Fixed-Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 25mg (T80/HCTZ25) Versus Telmisartan 80 mg (T80) Monotherapy as First Line Therapy in Patients With Severe Hypertension	\$5,643.00
Frank Pettyjohn	Bayer Healthcare Pharmaceuticals, Inc.	A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients with Essential Hypertension	\$4,501.00
Frank Pettyjohn	Novartis Pharmaceuticals	An 8 Week, Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination with Valsartan versus Valsartan Alone in Patients with Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus	\$55,782.00
Frank Pettyjohn	Wyeth Pharmaceuticals	Distribution of PCV13 Serotype Streptococcus Pneumoniae in Adults 50 Years and Older Presenting to Selected US Hospitals with Chest X-Ray Confirmed Community-Acquired Pneumonia	\$5,215.00
Total			\$71,141.00

FAMILY MEDICINE

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Carol Motley	HRSA 1 D56 HP23279-01-00	Pre Doctoral Training in Primary Care	\$176,513.00
Carol Motley	AFPRHB 110202	A Student Curriculum in FM for the Medical Students at the University of South Alabama School of Medicine.	\$44,500.00
Allen Perkins	HRSA 1 D58 HP23236-01-00	Residency Training in Primary Care Program	\$145,056.00
Allen Perkins	AFPRHB 100384	Student Preceptorship	\$30,000.00
Allen Perkins	AFPRHB 110201	A Resident Curriculum in Rural Family Medicine	\$37,000.00
		Total	\$433,069.00

INTERNAL MEDICINE

Diego Alvarez	AHA 0835134N-04	Infusion of Resident Endothelial Progenitors Promotes Repair of Microvascular Barrier During Acute Lung Injury	\$77,000.00
Martha Arrieta	Office of Minority Health	Subcontract Between Morehouse School of Medicine and University of South Alabama	\$18,542.00

INTERNAL MEDICINE (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Barbara Burckhardt	Roche	A Phase III, Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Effects of RO4607381 on Cardiovascular (CV) Risk in Stable CHD Patients with a Documented Recent Acute Coronary Syndrome (ACS), Protocol No. NC20971	\$5,762.00
Errol Crook	NIH 5 P20 MD002314-05	Broad-Based Research Collaboratives on Minority Health and Health Disparities	\$1,631,186.00
Michael Culpepper	Otsuka Maryland Research Institute	A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease	\$48,395.00
Michael Culpepper	Amgen	EVOLVE - Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events	\$9,488.00
Michael Culpepper	Amgen	Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis	\$9,578.00

INTERNAL MEDICINE (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Michael Culpepper	Dynavax/Accelovance	An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV to License Vaccine (Energix-B) among Adults (18-75 Years of Age) with Chronic Kidney Disease (CKD)	\$4,426.00
Michael Culpepper	Otsuka Pharmaceutical	Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimen in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)	\$15,175.00
Michael Culpepper	United Biosource Corporation	SPD405-404: A Phase-IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with Lanthanum Carbonate (Fosrenol)	\$2,183.00
Karen Fagan	Actelion Pharmaceuticals US, Inc.	An Open-Label, Multi-Center Study Employing a Targeted 6-MWT Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of MRI on Cardiac Remodeling	\$2,000.00
Karen Fagan	Actelion Pharmaceuticals US, Inc.	Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program	\$3,000.00

INTERNAL MEDICINE (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Karen Fagan	Actelion Pharmaceuticals US, Inc.	Drug Registry to PROSPECTively Describe Use of Room Temperature Stable Epoprostenol for Injection in Patients with Pulmonary Arterial Hypertension	\$5,500.00
Karen Fagan	Bayer Schering Pharma	From Targets to Novel Drugs	\$53,881.00
Karen Fagan	Gilead Sciences	Athena-1: A Randomized, Multicenter Study of Ambrisentan and Sildenafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Response to Sildenafil	\$6,800.00
Karen Fagan	Gilead Sciences	A Phase 2, Randomized, Double-Blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension	\$32,890.00
Karen Fagan	United Therapeutics Corporation	A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated with Tyvaso (treprostinil) Inhalation Solution	\$4,000.00
Karen Fagan	NIH 1 R13 HL108550-01	Grover Conference on Risk Factors in Pulmonary Hypertension	\$30,000.00

INTERNAL MEDICINE (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Johnson Haynes	Emmaus Medical	A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L-Glutamine Therapy for Sickle Cell Anemia and Sickle B-Thalassemia	\$19,375.00
Johnson Haynes	Novartis Pharmaceuticals	Incidence of Secondary Iron Overload in Adults with Sickle Cell Disease (SCD) Following Chronic, Intermittent Red Blood Cell (RBC) Transfusions	\$10,270.00
Jorge Herrera	Merck & Co., Inc.	A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 Hepatitis C Virus Infection	\$2,750.00
Jorge Herrera	Schering Plough Research Institute	Long-term Follow-up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C	\$25,290.00
Jorge Herrera	Schering Plough Research Institute	A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects with Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment with Peginterferon/Ribavirin	\$6,792.00

INTERNAL MEDICINE (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Jorge Herrera	Schering Plough Research Institute	A Phase 3 Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1	\$16,020.00
Jorge Herrera	Schering Plough Research Institute	A Phase 3 Safety and Efficacy Study of Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin	\$10,825.00
Jorge Herrera	Schering Plough Research Institute	A Phase 3 Safety and Efficacy Study of Erythropoietin Use During Treatment of Subjects With Chronic Hepatitis C With Boceprevir, Peginterferon Alpha-2b, and Ribavirin	\$13,373.00
Clara Massey	Bristol Myers-Squibb	A Phase 3 , Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation	\$10,835.00
Clara Massey	Novartis Pharmaceuticals	A Multicenter, Randomized, Double-Blind, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity, and Mortality in Patients with Chronic Heart Failure (NYHA Class II-IV)	\$8,858.00

INTERNAL MEDICINE (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Masahiko Oka & Ivan McMurtry	NIH 1 R21 HL106101-01	Cell-Targeted Drug Delivery for the Treatment of Pulmonary Arterial Hypertension	\$230,625.00
Bassam Omar	Hoffman-La Roche, Inc	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Cardiovascular Outcomes Study to Evaluate the Potential of Alegitazar to Reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D), #BC-22140	\$5,600.00
Bassam Omar	Schering Plough Research Institute	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome	\$23,100.00
John Vande Waa	HRSA 5 H12 HA23027-11-01	University of South Alabama Family Specialty Clinic	\$332,356.00
John Vande Waa	HRSA/UWCA-RW-USAF-1112	USA Family Specialty Clinic Grant	\$109,712.00
		Total	\$2,785,587.00

MICROBIOLOGY & IMMUNOLOGY

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Robert Lausch	Lion's Club	Lion's/USA Eye Research	\$18,120.00
Paul Brett & Mary Burtnick	NIH 1 R56 AI091783-01	Analysis of a Burkholderia Mallei Virulence-Associated Type V1 Secretion System	\$334,125.00
Paul Brett & Mary Burtnick	NIH 5 R21 A1088418-02	Development and Testing of Novel Glanders Vaccine Candidates	\$183,769.00
Joseph Brewer	NIH 5R01 GM061970-12	Homeostasis of the ER in Differentiating B Cells	\$316,082.00
Total			\$852,096.00

MITCHELL CANCER INSTITUTE*

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Thomas Butler	Genentech	An Observational Study of Treatment Pattern and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer	\$6,525.00
Thomas Butler	Hoffmann-LaRoche	An International Multi-Centre Open-Label 2-Arm Phase III Trial of Adjuvant Bevacizumab in Triple Negative Breast Cancer	\$16,001.00

MITCHELL CANCER INSTITUTE* (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Thomas Butler	Novartis Pharmaceuticals	A Randomized, Double-Blind Phase III Study of RAD001 10mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients with Advanced Pancreatic Neuroendocrine Tumor (NET)	\$16,323.00
Thomas Butler	Novartis Pharmaceuticals	A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer	\$17,760.00
Thomas Butler	Sarah Cannon Research Institute	A Randomized Trial of Ixempra vs. Taxol in Adjuvant Therapy of Triple-Negative Breast Cancer (TITAN)	\$7,650.00
Donato Dumlao	Wyeth Research	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Fixed-Dose of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation	\$4,396.00
Hung Khong	Abraxis	ABX238-BC08US/ A Phase I Study of Neoadjuvant Chemotherapy with Nanoparticle Albumin Bound Paclitaxel (Abraxane), Doxorubicin, and Cyclophosphamide (NAC) with or without Sorafenib in Patients with Stage I and Stage III Breast Cancer	\$24,000.00

MITCHELL CANCER INSTITUTE* (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Hung Khong	Abraxis/Celgene	A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitadine (Vidaza) with the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients with Advanced or Metastatic Solid Tumors and Breast Cancer	\$11,880.00
Hung Khong	Astellas	A Phase II, Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects Stage III (Unresectable) or Stage IV Melanoma	\$30,972.00
Hung Khong	Novartis Pharmaceuticals	A Randomized, Open-Label Study of 400mg Versus 800mg of Gleevec/Glivec (Imatinib Mesylate) in Patients with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints	\$4,540.00
Hung Khong	Pfizer	A Phase 3 Study of SU011248 in Combination with Paclitaxel Versus Bevacizumab with Paclitaxel in the First-Line Advanced Disease Setting in Patients Having Breast Cancer	\$425,919.00
Hung Khong	Wyeth Research	A Phase I/II , Open-Label Study of Neratinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer	\$26,350.00

MITCHELL CANCER INSTITUTE* (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Eddie Reed	US Biotest	Phase IIb Study Evaluating the Safety and Efficacy of TXA127 in the Reduction of Incidence and Severity of Thrombocytopenia in Patients Receiving Second-Line Combination of Gemcitabine and Platinum Therapy for Recurrent Ovarian Carcinoma	\$18,488.00
Rodney Rocconi	Precision Therapeutics, Inc.	A Non-Interventional Prospective Study of the Accuracy of the Precision Therapeutics, Inc. ChemoResponse Assay in Patients with Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer	\$34,515.00
William Taylor	NewLink	A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Hyperacute Pancreatic Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer	\$6,603.00
William Taylor	Novartis Pharmaceuticals	An Open-Label Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-Line Sunitinib Versus Sunitinib as First-Line Followed by Second-Line RAD001 in the Treatment of Patients with Metastatic Renal Cell Carcinoma	\$25,109.00
Total			\$677,031.00

***SAMSF Projects Only**

NEUROLOGY

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Bassam Bassam	Novartis Pharmaceuticals	A 24-Month Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients with Relapsing-Remitting Multiple Sclerosis	\$52,902.00
Paul Maertens	Pfizer	A Placebo-Controlled, Rising Dose, Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pregabalin in Pediatric Patients with Partial Onset Seizures	\$11,088.00
Paul Maertens	Pfizer	A 12-Month Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Pregabalin in Pediatric Patients with Partial Onset Seizures	\$6,544.00
Total			\$70,534.00

OBSTETRICS & GYNECOLOGY

Susan Baker	Sequenom	SQNM-T21-202/Noninvasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker	\$7,838.00
Cynthia Messer & Craig Sherman	March of Dimes	Centering Pregnancy Project @ The University of South Alabama	\$7,000.00

OBSTETRICS & GYNECOLOGY (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Botros Rizk	Novartis	A Double Blind, Randomized, Controlled, Multicenter, Proof of Efficacy Study of Oral BGS649 vs. Placebo (Each Coadministered with a Combined Oral Contraceptive) Assessing Pain Response in Patients with Refractory Endometriosis	\$28,101.00
Stephen Varner	ADPH C01114002 (GC# 11-002)	FY2011 Perinatal Coordinator Grant	\$11,500.00
		Total	\$54,439.00

ORTHOPAEDIC SURGERY

Jorge Alonso	McMaster University	Trial to Evaluate Ultrasound in the Treatment of Tibial Fractures (TRUST)	\$2,500.00
Valentina Grishko & Albert Pearsall	Musculoskeletal Transplant Foundation 090-395-02	Effect of Hyaluronic Acid on Chondrocyte Viability and Function During Cold Storage	\$100,000.00
		Total	\$102,500.00

PEDIATRICS

Karen Crissinger	Centocor, Inc.	A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients with Inflammatory Bowel Disease	\$41,136.00
-------------------------	----------------	---	-------------

PEDIATRICS (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Karen Crissinger	Johnson & Johnson PR&D	A Multicenter, Double-Blind, Parallel Group, and Open-Label Long-Term Maintenance Study to Evaluate the Safety and Efficacy of Rabeprazole Sodium Delayed Release Pediatric Bead Formulation in 1 to 11 Year Old Pediatric Subjects with Symptomatic and Erosive Gastroesophageal Reflux Disease	\$13,122.00
Karen Crissinger	Johnson & Johnson PR&D	A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed-Release Rabeprazole in 1 to 11 Month Old Pediatric Subjects with Symptomatic/Erosive Gastroesophageal Reflux Disease (GERD)	\$18,704.00
Benjamin Estrada	NIH/UAB N01-A1-30025-01-02	A Phase 3, Randomized, Placebo-controlled, Blinded Investigation of Oral Valganciclovir for Congenital CMV	\$17,550.00
Fabien Eyal	Biosynexus	A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis	\$264,421.00
Fabien Eyal	NIH/Yale University A08383(M09A10144)	Gene Targets for IVH (Subcontract)	\$1,485.00

PEDIATRICS (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Anne-Marie Kaulfers	ADPH C10114117 (CG# 11-205)	Endocrinology Clinic for State Newborn Screening Program	\$54,649.00
Katherine Savells	MedImmune, LLC	An Observational Prospective Study to Assess the Outcomes and Risk Factors of RSV Infection Among Premature Infants (32-35 weeks Gestational Age)	\$14,563.00
Lawrence Sindel	CFF C002-11/Center ID #101	Cystic Fibrosis Foundation Care Center	\$19,280.00
Lawrence Sindel	ADPH C10114116 (GC# 11-204)	Cystic Fibrosis Clinic for State Newborn Screening Program	\$40,440.00
Felicia Wilson	NIH/NCCF 020801	Children's Oncology Group Grant	\$5,400.00
Felicia Wilson	NIH/NCCF 98543-1234-02	Children's Oncology Group Grant	\$2,000.00
Felicia Wilson	ADPH C10114118 (GC# 11-206)	Comprehensive Sickle Cell Clinic for State Newborn Screening Program	\$40,440.00
Felicia Wilson	NIH/NCCF CA98543-08-02	Children's Oncology Group Grant	\$1,182.00
		Total	\$534,372.00

PHARMACOLOGY

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Natalie Bauer	NIH 1 R03 HL110828-01	Myoendothelial Junction and Microparticle Stimulation of PAH Vascular Lesions	\$74,250.00
Natalie Bauer	Gilead Sciences 10-090393-01	Potential Role of Circulating Microparticles in Pulmonary Arterial Hypertension: Progression and Treatment Assessment	\$50,000.00
Natalie Bauer	AHA 11SDG7390037	Microparticles as Mediators and Biomarkers of Pulmonary Arterial Hypertension	\$77,000.00
Mark Gillespie & Glenn Wilson	5 R01 HL058234-11	DNA Lesions & Gene Expression in Hypoxic Lung Disease	\$371,250.00
Ivan McMurtry & Salina Gairhe	AHA 11POST7720023	Sphingosine 1 Phosphate Mediates Sustained Vasoconstriction in Pulmonary Arterial Hypertension	\$41,740.00
Ivan McMurtry & Masahiko Oka	Pfizer 100404	Efficacy of Sunitinib, Terguride, and Their Contribution in Treatment of Severe Pulmonary Arterial Hypertension	\$100,000.00
Mykhaylo Ruchko & Viktor Pastukh	NIH 1 R21 HL102789-01A1	Role of Oxidative Modifications to D-loop Region in mTDNA Replication in Hypoxia	\$185,625.00
Troy Stevens & Glenda Bonilla	AHA 10PRE4320054-02	Essential Role of Lactate Dehydrogenase A (LDHA) in Lung Neo-Angiogenesis	\$21,770.00

PHARMACOLOGY (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Troy Stevens	NIH 1F31HL107122-01A1 Revised	Microtubule Stability in Lung Endothelium	\$27,528.00
Troy Stevens	NIH 5 R37 HL060024-14	Store Operated Ca2+ Entry: Lung Endothelial Permeability	\$371,250.00
Songwei Wu	NIH 1 R01 HL109186-01	T-type Calcium Channels and Neutrophil Transmigration	\$371,250.00
Total			\$1,691,663.00

PHYSIOLOGY

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Stephen Ballard	CFF Therapeutics BALLAR07XX0-03	Mucociliary Clearance Consortium	\$108,000.00
Michael Cohen	Otsuka Maryland Medicinal Laboratories	Evaluation of Cardioprotective Effect of Cangrelor in Cardiac Ischemia Reperfusion Injury Model in Cynomolgus Monkeys Using Open Chest Method	\$34,239.00
James Downey	Bayer HealthCare AG	Inhibition of Ischemic Injury by Activation of A1 Receptors by a New A1 Receptor Agonist BR-5470	\$9,375.00
James Downey	NIH 5 R01 HL020648-31	Physical Factors and Coronary Flow	\$287,231.00

PHYSIOLOGY (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Thomas Lincoln	NIH 2 R01 HL066164-11	Expression of PKG in Vascular Smooth Muscle Cells	\$371,250.00
Mark Taylor	NIH 5 R01 HL085887-05 Revised	Coronary Artery Regulation by Small Conduction Ca ²⁺ -activated K ⁺ Channels	\$257,250.00
Mary Townsley	GlaxoSmithKline	Research Collaboration Agreement - GSK-MPCEDD (TRPV4)	\$18,375.00
Mary Townsley	NIH 5 T32 HL076125-08	Training in Cell Signaling and Lung Pathobiology	\$199,476.00
David Weber	NIH 5 R01 HL084159-04	Reactive Oxygen Species Regulation on Vascular Smooth Muscle Cell Migration	\$330,750.00
		Total	\$1,615,946.00

SURGERY

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Patrick Bosarge	KCI USA	A Prospective Study Examining Clinical Outcomes Associated with the Management of the Open Abdomen with the ABTHERA Open Abdomen Negative Pressure Therapy System and Barker's Vacuum Packing Technique	\$4,716.00

SURGERY (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
Arnold Luterman	Mylan Pharmaceuticals	Prospective Evaluation of the Effects of Topical Therapy with Sulfamylon for 5% Topical Solution on Autograft Healing in Subjects with Thermal Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group	\$13,750.00
Arnold Luterman	Rib-X Pharmaceuticals	A Phase 2 Exploratory Study of Objective Endpoints in Subjects with Acute Bacterial Skin and Skin Structure Infections Treated with Delefloxacin, Vancomycin, or Linezolid	\$3,000.00
Arnold Luterman	The Medicines Company	A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin versus IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infection (SOLO I)	\$2,500.00
William Richards	NIH/VUMC VUMC 37157	Biomagnetic Characterization of Gastric Dysrhythmias (Subcontract)	\$22,287.00

SURGERY (cont'd)

Principal Investigator	Agency	Project Title	Fiscal Year Funding
William Richards	NIH 5 R01 DK058197-08	Biomagnetic Signals of Intestinal Ischemia	\$86,137.00
Paul Rider	Ethicon Endo-Surgery	Assessment of a Slotted Anoscope that Facilitates Hemorrhoidectomy	\$2,672.00
Paul Rider	Gore & Associates	Efficacy of Bioabsorbable Staple Line Reinforcement in Colorectal and Coloanal Anastomoses	\$6,300.00
		Total	\$141,362.00